SSTR2 and neuroendocrine neoplasm: Our system achieved a tumor uptake of 2.4–7.0% ID/g at 24 hours post-injection and a mean tumor absorbed dose of 0.3 Gy/MBq, which are comparable to studies that assessed the direct targeting of neuroendocrine tumor cells overexpressing SSTR2 with 177Lu-DOTATATE in animal models (44, 45).